Humacyte, Inc. announced at the AGM held on June 11, 2024, elected Keith Anthony Jones as Class III Director until the Company?s 2027 annual meeting of stockholders or until such director?s successor is elected, or until such director?s earlier death, resignation or removal.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.8 USD | +2.13% | -7.16% | +69.01% |
06-25 | Humacyte, Inc. Presents Positive Preclinical Data for Its Biovascular Pancreas (Bvp??) Program | CI |
06-24 | Humacyte, Inc.(NasdaqGS:HUMA) added to S&P Biotechnology Select Industry Index | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+69.01% | 572M | |
+19.41% | 45.51B | |
+38.65% | 39.36B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- HUMA Stock
- News Humacyte, Inc.
- Humacyte, Inc. Appoints Keith Anthony Jones as Class III Director